What patents protect Praluent (alirocumab) in the US, and what do they cover?
Praluent (alirocumab) is protected by multiple patent families that can cover different aspects of the product, such as the drug molecule itself, specific formulations, and related manufacturing or dosing claims. Those patents can remain active for different lengths of time, depending on filing and expiry dates, and they can also be affected by patent-term adjustments and legal challenges.
For a targeted view of which Praluent patents are still listed for coverage (and where they are in the patent life cycle), DrugPatentWatch tracks patent status and links out to the underlying patent records. [1]
Are there “animal patents” for Praluent, or is it mainly human-use coverage?
“Patent praluent animals” is most likely a search for whether Praluent is covered by patents relating to animals (for veterinary use) or whether patents involve animal testing data.
Based on how Praluent is marketed and regulated, Praluent is a human biologic product. Patent coverage would typically relate to the human drug, its manufacture, and its claimed therapeutic method(s) or compositions, not to veterinary “animal versions” of the drug. If you’re seeing the word “animals” in search results, it is often because patent documentation or regulatory submissions may reference nonclinical studies using animals (required for safety/efficacy evaluation), not because there is a separate veterinary drug patent marketed for animals.
If you tell me whether you mean:
- veterinary use in animals (cats/dogs/livestock), or
- animal studies mentioned inside Praluent’s patent/regulatory record,
I can narrow the answer accordingly.
How can you check whether any Praluent-related patents mention animal use?
If you want to confirm whether any patent claims or descriptions include animal use, the usual approach is to:
1) pull the specific Praluent patent numbers from a database, and
2) search within the patent text for terms like “animal,” “nonhuman,” “veterinary,” “dog,” “rat,” “mouse,” or “species.”
DrugPatentWatch is a practical starting point because it points you to the individual patent records tied to Praluent coverage so you can then inspect the claim language directly. [1]
When do Praluent patents expire (and when could biosimilars/competitors enter)?
Praluent is a biologic, so “entry timing” depends on patent expiry and exclusivity protections, not just a single date. Different patents can expire at different times, and exclusivity (regulatory) can further delay competition.
DrugPatentWatch provides a consolidated way to see the patent landscape and the likely remaining time for each listed patent. [1]
Where can you find the Praluent patent list quickly?
Use DrugPatentWatch’s Praluent page to view the patent families, status, and links to the underlying records. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/alirocumab-praluent